Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.58 |
| ▸ | LMNA | P02545 | 2/20 | 0.58 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.58 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.58 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.58 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.58 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.58 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.42 |
| ▸ | ANPEP | P15144 | 3/20 | 0.41 |
| ▸ | LAP3 | P28838 | 3/20 | 0.41 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.41 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.40 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.37 |
| ▸ | CACNA2D1 | P54289 | 2/20 | 0.37 |
| ▸ | CACNB3 | P54284 | 1/20 | 0.37 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.37 |
| ▸ | PGR | P06401 | 1/20 | 0.37 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29728566 | 0.92 | TSHR (0.60) | TSHRLMNACHRM2CHRM4CHRM1 | |
| SCHEMBL9117588 | 0.85 | LMNA (0.54) | TSHRLMNACHRM2CHRM4CHRM1 | |
| SCHEMBL28522362 | 0.85 | CHRM2 (0.54) | TSHRLMNACHRM2CHRM4CHRM1 | |
| SCHEMBL28518105 | 0.85 | CHRM2 (0.54) | TSHRLMNACHRM2CHRM4CHRM1 | |
| SCHEMBL3373149 | 0.85 | CHRM2 (0.54) | TSHRLMNACHRM2CHRM4CHRM1 | |
| SCHEMBL10623266 | 0.83 | LMNA (0.52) | TSHRLMNACHRM2CHRM4CHRM1 | |
| SCHEMBL18283384 | 0.83 | LMNA (0.52) | TSHRLMNACHRM2CHRM4CHRM1 | |
| SCHEMBL28397825 | 0.81 | LMNA (0.50) | TSHRLMNACHRM2CHRM4CHRM1 | |
| SCHEMBL28856960 | 0.80 | LMNA (0.48) | TSHRLMNACHRM2CHRM4CHRM1 | |
| SCHEMBL23725742 | 0.79 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024094637-A1 | PROCESS FOR THE PREPARATION OF CYCLIC KETONES | ARXADA AG (CH) | 2024-05-10 | — | — | WO | disclosed |
| US-20190177469-A1 | CURABLE RESIN COMPOSITION | CANON KABUSHIKI KAISHA (JP) | 2019-06-13 | — | — | US | disclosed |
| EP-2755949-B1 | FUNGICIDAL 4-SUBSTITUTED-3-{PHENYL[(HETEROCYCLYLMETHOXY)IMINO]METHYL}-1,2,4-OXADIZOL-5(4H)-ONE DERIVATIVES | BAYER IP GMBH (DE) | 2015-10-21 | — | — | EP | disclosed |
| EP-2797891-B1 | FUNGICIDAL 3-[(PYRIDIN-2-YLMETHOXYIMINO)(PHENYL)METHYL]-2-SUBSTITUTED-1,2,4-OXADIAZOL-5(2H)-ONE DERIVATIVES | BAYER IP GMBH (DE) | 2015-09-30 | — | — | EP | disclosed |
| US-9090600-B2 | Fungicidal 4-substituted-3-{phenyl[(heterocyclylmethoxy)imino]methyl}-1,2,4-oxadizol-5(4H)-one derivatives | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-07-28 | — | — | US | disclosed |
| US-9051255-B2 | Piperazinyl cyclohexane compounds as GPR38 agonists | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2015-06-09 | — | — | US | disclosed |
| US-9045423-B2 | Prophylactic and/or therapeutic agent for anemia comprising tetrahydroquinoline compound as active ingredient | KOWA COMPANY, LTD. (JP) | 2015-06-02 | — | — | US | disclosed |
| US-20140349848-A1 | FUNGICIDAL 4-SUBSTITUTED-3--1,2,4-OXADIZOL-5(4H)-ONE DERIVATIVES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-11-27 | — | — | US | disclosed |
| US-20140249144-A1 | PROPHYLACTIC AND/OR THERAPEUTIC AGENT FOR ANEMIA COMPRISING TETRAHYDROQUINOLINE COMPOUND AS ACTIVE INGREDIENT | KOWA COMPANY, LTD. (JP) | 2014-09-04 | — | — | US | disclosed |
| US-20140221391-A1 | CYCLOHEXANE DERIVATIVE COMPOUND | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2014-08-07 | — | — | US | disclosed |
| US-20050037925-A1 | 3-phenoxy-4-pyridazinol derivatives and herbicide composition containing the same | SANKYO AGRO COMPANY, LIMITED (JP) | 2005-02-17 | — | — | US | disclosed |
| EP-1426365-A1 | 3-PHENOXY-4-PYRIDAZINOL DERIVATIVE AND HERBICIDE COMPOSITION CONTAINING THE SAME | Sankyo Agro Company, Limited (JP) | 2004-06-09 | — | — | EP | disclosed |
| WO-2003106435-A1 | FUSED-RING PYRIMIDIN-4(3H)-ONE DERIVATIVES, PROCESSES FOR THE PREPARATION AND USES THEREOF | SANKYO COMPANY, LIMITED (JP) | 2003-12-24 | — | — | WO | disclosed |
| EP-0934938-B1 | SUBSTITUTED BENZOYLAMINOTHIAZOLE DERIVATIVES AND DRUGS CONTAINING THE SAME | ZERIA PHARM CO LTD (JP) | 2003-01-15 | — | — | EP | disclosed |
| US-6121301-A | ADMINISTERING TO PREVENT OR TREAT GASTROINTESTINAL DYSMOTILITY; COMPOUNDS SUCH AS 2-((N-(3-CYANOBENZOYL)AMINO)-4-((3-DIISOPROPYLAMINOPROPYL)AMINOCARBONYL)-1,3-THIAZOLE | ZERIA PHARMACEUTICAL CO., LTD. (JP) | 2000-09-19 | — | — | US | disclosed |
| US-6005116-A | HAVE INHIBITION ACTIVITIES AGAINST TYPE A-MONOAMINE OXIDASE; TREATING OR PREVENTING DEPRESSION, PARKINSON'S DISEASE, ALZEHEIMER'S DEMENTIA, OR CEREBROVASCULAR DEMENTIA | SANKYO COMPANY, LIMITED (JP) | 1999-12-21 | — | — | US | disclosed |
| EP-0934938-A1 | SUBSTITUTED BENZOYLAMINOTHIAZOLE DERIVATIVES AND DRUGS CONTAINING THE SAME | ZERIA PHARMACEUTICAL CO., LTD. (JP) | 1999-08-11 | — | — | EP | disclosed |
| US-5908858-A | OSTEOPOROSIS; LEUKOTRIENE INHIBITOR | SANKYO COMPANY, LIMITED (JP) | 1999-06-01 | — | — | US | disclosed |
| EP-0885891-A1 | ISOXAZOLE DERIVATIVES | SANKYO COMPANY LIMITED (JP) | 1998-12-23 | — | — | EP | disclosed |
| EP-0799823-A1 | 1,2-Diphenylpyrrole derivatives, their preparation and their therapeutic uses | SANKYO COMPANY LIMITED (JP) | 1997-10-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140249144-A1 | PROPHYLACTIC AND/OR THERAPEUTIC AGENT FOR ANEMIA COMPRISING TETRAHYDROQUINOLINE COMPOUND AS ACTIVE INGREDIENT | EPOR, HBG1, HBG2 | TSHR 806/4885LMNA 4334/4885CHRM2 3775/4885 |
| US-20140349848-A1 | FUNGICIDAL 4-SUBSTITUTED-3--1,2,4-OXADIZOL-5(4H)-ONE DERIVATIVES | CYP4X1, CYP4B1, CYP4Z1 | TSHR 1558/4885LMNA 3306/4885CHRM2 605/4885 |
| US-20140221391-A1 | CYCLOHEXANE DERIVATIVE COMPOUND | HRH2, CBR1, HRH4 | TSHR 1601/4885LMNA 1962/4885CHRM2 107/4885 |
| US-20050037925-A1 | 3-phenoxy-4-pyridazinol derivatives and herbicide composition containing the same | CBR3, DDT, CHRM2 | TSHR 600/4885LMNA 3977/4885CHRM2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.